Evidence map›Paper›PMID 41923586›Full record

ReviewJournal of microbiology (Seoul, Korea)2026

Emerging synthetic biology-assisted technologies for overcoming antibiotic resistance: CRISPR-Cas, bacteriophage, microbiome, and metabolic engineering-based solutions.

Yujeong Oh, Hyunjin Lee, Sungho Jang

Abstract readReview
In one paragraph

Review in Journal of microbiology (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pioneering strategies for overcoming bacterial drug resistance.Journal of microbiology (Seoul, Korea) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yujeong OhDepartment of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
Hyunjin LeeResearch Center for Bio Materials & Process Development, Incheon National University, Incheon 22012, Republic of Korea.
Sungho JangDepartment of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.

Funding

Incheon National UniversityMinistry of Science and ICT RS-2025-02214910National Research Foundation of Korea
6 · The paper itself

Abstract

Antibiotic resistance has become a critical global health challenge due to the decreased efficacy of existing antibiotics and the emergence of multidrug-resistant pathogens. In particular, the rapid horizontal transfer of resistance genes and the diverse mechanisms by which bacteria acquire resistance have significantly undermined the effectiveness of conventional therapeutic strategies, revealing fundamental limitations in current infectious disease management. In this context, synthetic biology provides a promising framework to overcome the limitations of conventional antibiotics by integrating engineering principles with bioengineering approaches, thereby enabling precise and programmable control of biological processes. These synthetic biology-based approaches offer substantial potential for developing sustainable and highly specific antimicrobial strategies. This review comprehensively examines recent advances in synthetic biology-assisted antimicrobial strategies, including CRISPR-Cas systems, bacteriophage engineering, microbiome engineering, and metabolic engineering-driven antibiotic discovery. Collectively, these approaches represent a precision antimicrobial paradigm that enables selective targeting of resistant bacteria while preserving microbiome homeostasis. These strategies also provide new directions for limiting resistance dissemination and guiding the development of next-generation therapeutics.

Indexed as

BacteriaBacteriophagesCRISPR-Cas SystemsDrug Resistance, BacterialDrug Resistance, MicrobialMetabolic EngineeringMicrobiotaSynthetic BiologyAnti-Bacterial AgentsHumansAnti-Bacterial Agentsantibiotic resistancebacteriophage engineeringCRISPR-Casmetabolic engineeringmicrobiome engineeringsynthetic biology

Identifiers

PMID41923586
PMCPMC13577098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.